Study of efficacy of selective estrogen receptor modulator: Ormeloxifene in the management of heavy menstrual bleeding in perimenopausal patients: A prospective interventional study

• Author Details:   
• Nitin Naresh Kulkarni
• Priyanka Lalitkumar Agrawal
• Aakanksha Bhagirathrao Deshmukh
• Aakruti Atul Ganla ^*

---

Background: Menorrhagia is a common complaint of about 10-33% of women in perimenopausal period. Ormeloxifene is a third – generation selective estrogen receptor modulator (SERM) highly efficacious in the management of Heavy Menstrual Bleeding, but not commonly used at present.

Aim & Objective: To determine the therapeutic efficacy of SERM in management of HMB.

Materials and Methods: An institution based prospective study was conducted on 150 patients in the age group of 35-45 years who were treated with 60mg ormeloxifene twice a week for the first 3 months and once weekly for the next 3 months. The outcome was assessed based on menstrual blood loss in terms of PABC score, endometrial thickness and hemoglobin concentration.

Results: The treatment effects of ormeloxifene, in patients of Heavy Menstrual bleeding was found * PBAC score has decreased to 95 ± 28.35 in 6 months from the basal value of 244.15 ± 35.04. *endometrial thickness (in mm) has decreased to 6.70 ± 1.22 at 6 months, from the basal value of 9.57± 1.15 (mm). Haemoglobin levels have increased to 9.57 ± 0.84 at 6 months from the basal value of 7.52 ± 0.75(gm/dl).

Conclusion: Ormeloxifene is very safe, cost-effective and with manageable side effects and hence, can be used as the drug of choice in patients with HMB.